Pnc Financial Services Group, Inc. Ardelyx, Inc. Transaction History

Pnc Financial Services Group, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$5.89 - $9.31 $1,066 - $1,685	-181 Reduced 94.27%	11 $0
Q1 2024 May 10, 2024	BUY	$6.05 - $9.74 $1,089 - $1,753	180 Added 1500.0%	192 $1,000
Q4 2023 Feb 09, 2024	BUY	$3.29 - $6.64 $39 - $79	12 New	12 $0
Q4 2022 Feb 10, 2023	BUY	$1.22 - $2.85 $488 - $1,140	400 New	400 $1,000
Q3 2019 Nov 08, 2019	SELL	$2.15 - $6.28 $86,000 - $251,200	-40,000 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$1.88 - $3.35 $37,600 - $67,000	20,000 Added 100.0%	40,000 $0
Q3 2018 Nov 09, 2018	BUY	$3.75 - $4.65 $75,000 - $93,000	20,000 New	20,000 $0
Q2 2018 Aug 10, 2018	SELL	$3.7 - $5.8 $22,022 - $34,521	-5,952 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$4.85 - $7.8 $28,867 - $46,425	5,952	5,952 $0

219

141M

1.08M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $815M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.